These CEOs want to market the next Ozempic. Just don’t call it that
Biopharma chiefs don’t like being labeled as followers, especially not in obesity. Just ask Robert Bradway, Amgen chairman and CEO. At the J.P. Morgan Healthcare Conference this week, Bradway was asked what he sees as the pros and cons to Amgen’s …